Therapeutic Drug Monitoring to Spike to $2.69 Billion by 2019
This newly published “Therapeutic Drug Monitoring” report that therapeutic drug monitoring (TDM) will spike to $2.69 billion by 2019.
Therapeutic drug monitoring can be categorized into seven main modalities: antiepileptics, antiarrhythmics, antibiotics, antineoplastics, bronchodilators, immunosuppressives and HIV/AIDS drugs. The global therapeutic drug monitoring market is dominated by eight major suppliers that account for a combined 88.3% of the global market. The U.S. market is expected to grow to $1.84 billion by 2019 at a CAGR of 12.6%.
The “Therapeutic Drug Monitoring” report covers:
- Chemiluminescence
- High Pressure Liquid Chromatography (HPLC)
- Gas Chromatography/Mass Spectrometry
- Liquid Chromatography/Mass Spectrometry
- Flucytosine
- Triazoles
- Itraconazole
- Voriconazole
- Posaconazole
- Enzyme Immunoassays
- Enzyme Multiplied Immunoassay Technique
- Enzyme Donor Immunoassays
- Radio Immunoassays
- Fluorescence Polarization Immunoassays
- Lateral Flow Immunoassays
- Particle Enhanced Turbidimetric Inhibition Immunoassays
- Affinity Chrome Mediated Immunoassays
The “Therapeutic Drug Monitoring” report examines companies manufacturing therapeutic drug monitoring equipment and supplies in the world.
Companies covered include:
- Abaxis,
- Abbott,
- Alere,
- Alfa Wassermann,
- AMS,
- Beckman Coulter,
- BioMerieux,
- Carolina Chemistries,
- DiaSorin,
- Grifols,
- Horiba,
- Medica,
- Nova Biomedical,
- Ortho Clinical Diagnostics,
- Polymedico,
- Randox,
- Roche and Siemens.